ArticleCell stem cell2018

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Michael Y Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.